文献速递冠心病

随机试验评估经皮冠状动脉介入治疗慢性完全闭塞病变

Randomized Trial Evaluating Percutaneous Coronary Intervention for the Treatment of Chronic Total Occlusion.
PubMed 文献 · Circulation · 2019-01-01

这项开放标签、多中心、随机、非劣效性试验将834例适合PCI的患者分配至CTO-PCI策略组或无CTO-PCI策略组,主要终点为死亡、心肌梗死、卒中或任何血运重建的复合终点。中位随访4.0年,两组主要终点发生率无显著差异(22.3% vs 22.4%,HR 1.03,95%CI 0.77-1.37,P=0.86)。CTO-PCI成功率高(90.6%),但研究因招募缓慢提前终止,把握度不足且交叉率高。

要点

  • CTO-PCI成功率高(90.6%),但与不进行CTO-PCI相比未显著降低主要不良心血管事件。
  • 两组主要终点发生率相似(22.3% vs 22.4%,HR 1.03,95%CI 0.77-1.37,P=0.86)。
  • 研究因招募缓慢提前终止,临床终点把握度低且组间交叉率高(19.6%),结论需谨慎解读。

核心结论

  • CTO-PCI可行且成功率高,但与不进行CTO-PCI策略相比,主要不良心血管事件发生率无显著差异。
  • 研究受限于临床终点把握度低和组间高交叉率,结论需谨慎解读。

研究设计与样本

  • 开放标签、多中心、随机、非劣效性试验,计划入组1284例,因招募缓慢提前终止,实际随机834例。
  • 患者被分配至CTO-PCI策略组(n=417)或无CTO-PCI策略组(n=398),允许术者酌情对阻塞性非CTO病变行PCI。
  • 主要终点为死亡、心肌梗死、卒中或任何血运重建的复合终点;中位随访4.0年(IQR 2.4-5.1年)。

主要发现

  • CTO-PCI总体成功率为90.6%。
  • 无CTO-PCI策略组中78例(19.6%)在随机化后3天内交叉接受分期CTO-PCI。
  • CTO-PCI相关严重非致命并发症发生于3例患者(1例卒中、1例心脏压塞、1例因冠状动脉内血栓导致反复室性快速心律失常)。
  • 两组约半数患者接受非CTO病变PCI(平均1.3处病变),残余SYNTAX评分相似(3.7±5.4 vs 4.0±5.9,P=0.42)。
  • 主要终点发生率两组无显著差异(22.3% vs 22.4%,HR 1.03,95%CI 0.77-1.37,P=0.86)。

临床怎么用

  • 对于适合PCI的CTO患者,CTO-PCI策略可考虑用于缓解症状或改善生活质量,但不应期望降低硬终点事件。
  • 临床决策需结合患者症状、缺血负荷及手术风险个体化评估,尤其注意CTO-PCI相关严重并发症风险。

局限性

  • 研究因招募缓慢提前终止,临床终点把握度低。
  • 组间交叉率高(19.6%),可能稀释意向性治疗分析的治疗效应。
  • 开放标签设计可能引入偏倚。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Procedural results for percutaneous coronary intervention (PCI) in coronary vessels with chronic total occlusion (CTO) have improved in recent years, and PCI strategies have moved toward more complete revascularization with more liberal use of CTO-PCI. However, evidence evaluating CTO-PCI is limited to observational studies and small clinical trials. METHODS: In this open-label, multicenter, randomized, noninferiority trial, PCI-eligible patients were assigned to receive either 1 of 2 strategies: PCI or no PCI for the qualifying de novo CTO lesion with the option for PCI of obstructive non-CTO lesions at the discretion of the operator. The primary end point was a composite of death, myocardial infarction, stroke, or any revascularization. Health-related quality of life was assessed at baseline and at 1, 6, 12, 24, and 36 months. Because of slow recruitment, the trial was stopped before completion of the 1284 planned enrollments. RESULTS: Between March 2010 and September 2016, 834 patients were randomly assigned to the CTO-PCI (n=417) or no CTO-PCI (n=398) strategy. Among the patients assigned to the no CTO-PCI strategy, 78 (19.6%) crossed over to receive staged CTO-PCI within 3 days of randomization. The overall CTO-PCI success rate was 90.6%. Serious nonfatal complications associated with CTO-PCI occurred in 3 patients (1 stroke, 1 cardiac tamponade, and 1 patient with recurrent episodes of ventricular tachyarrhythmia induced by intracoronary thrombus). Approximately half of the patients in each group underwent PCI for an average of 1.3 non-CTO lesions, resulting in a comparable residual SYNTAX score (Synergy Between PCI With TAXUS and Cardiac Surgery; 3.7±5.4 versus 4.0±5.9, P=0.42) confined to non-CTO vessels. During a median follow-up of 4.0 years (interquartile range, 2.4 to 5.1 years), there was no significant difference between the CTO-PCI and the no CTO-PCI strategies in the incidence of the primary end point (22.3% versus 22.4%, hazard ratio, 1.03; 95% CI, 0.77 to 1.37; P=0.86). Both CTO-PCI and no CTO-PCI strategy were associated with significant improvements but without between-group differences in disease-specific health status that was sustained through 36 months. CONCLUSIONS: CTO-PCI was feasible with high success rates. There was no difference in the incidence of major adverse cardiovascular events with CTO-PCI versus no CTO-PCI, but the study was limited by low power for clinical end points and high crossover rates between groups. CLINICAL TRIAL REGISTRATION: URL: https://www.clinicaltrials.gov . Unique identifier: NCT01078051.

来源:Circulation,查看原文。版权归原作者所有。

引用

  1. Lee SW, Lee PH, Ahn JM, et al. Randomized Trial Evaluating Percutaneous Coronary Intervention for the Treatment of Chronic Total Occlusion. Circulation. 2019. PMID: 30813758. doi:10.1161/CIRCULATIONAHA.118.031313

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。